Cargando…
Plasmonic Fluor-Enhanced Antigen Arrays for High-Throughput, Serological Studies of SARS-CoV-2
[Image: see text] Serological testing for acute infection or prior exposure is critical for patient management and coordination of public health decisions during outbreaks. Current methods have several limitations, including variable performance, relatively low analytical and clinical sensitivity, a...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Chemical Society
2022
|
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9344907/ https://www.ncbi.nlm.nih.gov/pubmed/35867632 http://dx.doi.org/10.1021/acsinfecdis.2c00086 |
_version_ | 1784761316637933568 |
---|---|
author | Qavi, Abraham J. Wu, Chao Lloyd, Matthew Zaman, Mohammad Mahabub-Uz Luan, Jingyi Ballman, Claire Leung, Daisy W. Crick, Scott L. Farnsworth, Christopher W. Amarasinghe, Gaya K. |
author_facet | Qavi, Abraham J. Wu, Chao Lloyd, Matthew Zaman, Mohammad Mahabub-Uz Luan, Jingyi Ballman, Claire Leung, Daisy W. Crick, Scott L. Farnsworth, Christopher W. Amarasinghe, Gaya K. |
author_sort | Qavi, Abraham J. |
collection | PubMed |
description | [Image: see text] Serological testing for acute infection or prior exposure is critical for patient management and coordination of public health decisions during outbreaks. Current methods have several limitations, including variable performance, relatively low analytical and clinical sensitivity, and poor detection due to antigenic drift. Serological methods for SARS-CoV-2 detection for the ongoing COVID-19 pandemic suffer from several of these limitations and serves as a reminder of the critical need for new technologies. Here, we describe the use of ultrabright fluorescent reagents, Plasmonic Fluors, coupled with antigen arrays that address a subset of these limitations. We demonstrate its application using patient samples in SARS-CoV-2 serological assays. In our multiplexed assay, SARS-CoV-2 antigens were spotted into 48-plex arrays within a single well of a 96-well plate and used to evaluate remnant laboratory samples of SARS-CoV-2 positive patients. Signal-readout was performed with Auragent Bioscience’s Empower microplate reader, and microarray analysis software. Sample volumes of 1 μL were used. High sensitivity of the Plasmonic Fluors combined with the array format enabled us to profile patient serological response to eight distinct SARS-CoV-2 antigens and evaluate responses to IgG, IgM, and IgA. Sensitivities for SARS-CoV-2 antigens during the symptomatic state ranged between 72.5 and 95.0%, specificity between 62.5 and 100%, and the resulting area under the curve values between 0.76 and 0.97. Together, these results highlight the increased sensitivity for low sample volumes and multiplex capability. These characteristics make Plasmonic Fluor-enhanced antigen arrays an attractive technology for serological studies for the COVID-19 pandemic and beyond. |
format | Online Article Text |
id | pubmed-9344907 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | American Chemical Society |
record_format | MEDLINE/PubMed |
spelling | pubmed-93449072022-08-03 Plasmonic Fluor-Enhanced Antigen Arrays for High-Throughput, Serological Studies of SARS-CoV-2 Qavi, Abraham J. Wu, Chao Lloyd, Matthew Zaman, Mohammad Mahabub-Uz Luan, Jingyi Ballman, Claire Leung, Daisy W. Crick, Scott L. Farnsworth, Christopher W. Amarasinghe, Gaya K. ACS Infect Dis [Image: see text] Serological testing for acute infection or prior exposure is critical for patient management and coordination of public health decisions during outbreaks. Current methods have several limitations, including variable performance, relatively low analytical and clinical sensitivity, and poor detection due to antigenic drift. Serological methods for SARS-CoV-2 detection for the ongoing COVID-19 pandemic suffer from several of these limitations and serves as a reminder of the critical need for new technologies. Here, we describe the use of ultrabright fluorescent reagents, Plasmonic Fluors, coupled with antigen arrays that address a subset of these limitations. We demonstrate its application using patient samples in SARS-CoV-2 serological assays. In our multiplexed assay, SARS-CoV-2 antigens were spotted into 48-plex arrays within a single well of a 96-well plate and used to evaluate remnant laboratory samples of SARS-CoV-2 positive patients. Signal-readout was performed with Auragent Bioscience’s Empower microplate reader, and microarray analysis software. Sample volumes of 1 μL were used. High sensitivity of the Plasmonic Fluors combined with the array format enabled us to profile patient serological response to eight distinct SARS-CoV-2 antigens and evaluate responses to IgG, IgM, and IgA. Sensitivities for SARS-CoV-2 antigens during the symptomatic state ranged between 72.5 and 95.0%, specificity between 62.5 and 100%, and the resulting area under the curve values between 0.76 and 0.97. Together, these results highlight the increased sensitivity for low sample volumes and multiplex capability. These characteristics make Plasmonic Fluor-enhanced antigen arrays an attractive technology for serological studies for the COVID-19 pandemic and beyond. American Chemical Society 2022-07-22 2022-08-12 /pmc/articles/PMC9344907/ /pubmed/35867632 http://dx.doi.org/10.1021/acsinfecdis.2c00086 Text en © 2022 The Authors. Published by American Chemical Society https://creativecommons.org/licenses/by-nc-nd/4.0/Permits non-commercial access and re-use, provided that author attribution and integrity are maintained; but does not permit creation of adaptations or other derivative works (https://creativecommons.org/licenses/by-nc-nd/4.0/). |
spellingShingle | Qavi, Abraham J. Wu, Chao Lloyd, Matthew Zaman, Mohammad Mahabub-Uz Luan, Jingyi Ballman, Claire Leung, Daisy W. Crick, Scott L. Farnsworth, Christopher W. Amarasinghe, Gaya K. Plasmonic Fluor-Enhanced Antigen Arrays for High-Throughput, Serological Studies of SARS-CoV-2 |
title | Plasmonic Fluor-Enhanced Antigen Arrays for High-Throughput,
Serological Studies of SARS-CoV-2 |
title_full | Plasmonic Fluor-Enhanced Antigen Arrays for High-Throughput,
Serological Studies of SARS-CoV-2 |
title_fullStr | Plasmonic Fluor-Enhanced Antigen Arrays for High-Throughput,
Serological Studies of SARS-CoV-2 |
title_full_unstemmed | Plasmonic Fluor-Enhanced Antigen Arrays for High-Throughput,
Serological Studies of SARS-CoV-2 |
title_short | Plasmonic Fluor-Enhanced Antigen Arrays for High-Throughput,
Serological Studies of SARS-CoV-2 |
title_sort | plasmonic fluor-enhanced antigen arrays for high-throughput,
serological studies of sars-cov-2 |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9344907/ https://www.ncbi.nlm.nih.gov/pubmed/35867632 http://dx.doi.org/10.1021/acsinfecdis.2c00086 |
work_keys_str_mv | AT qaviabrahamj plasmonicfluorenhancedantigenarraysforhighthroughputserologicalstudiesofsarscov2 AT wuchao plasmonicfluorenhancedantigenarraysforhighthroughputserologicalstudiesofsarscov2 AT lloydmatthew plasmonicfluorenhancedantigenarraysforhighthroughputserologicalstudiesofsarscov2 AT zamanmohammadmahabubuz plasmonicfluorenhancedantigenarraysforhighthroughputserologicalstudiesofsarscov2 AT luanjingyi plasmonicfluorenhancedantigenarraysforhighthroughputserologicalstudiesofsarscov2 AT ballmanclaire plasmonicfluorenhancedantigenarraysforhighthroughputserologicalstudiesofsarscov2 AT leungdaisyw plasmonicfluorenhancedantigenarraysforhighthroughputserologicalstudiesofsarscov2 AT crickscottl plasmonicfluorenhancedantigenarraysforhighthroughputserologicalstudiesofsarscov2 AT farnsworthchristopherw plasmonicfluorenhancedantigenarraysforhighthroughputserologicalstudiesofsarscov2 AT amarasinghegayak plasmonicfluorenhancedantigenarraysforhighthroughputserologicalstudiesofsarscov2 |